Welcome to our dedicated page for Cerus SEC filings (Ticker: CERS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for Cerus Corporation (NASDAQ: CERS), a biomedical products company focused on blood transfusion safety and pathogen-protected blood components. These filings offer detailed information on the company’s financial performance, business risks, and corporate governance.
Investors can review current reports on Form 8-K, which Cerus uses to furnish press releases announcing quarterly financial results, such as second and third quarter 2025 earnings. These 8-K filings summarize product revenue from INTERCEPT platelet, plasma, and INTERCEPT Fibrinogen Complex (IFC) sales, government contract revenue related to INTERCEPT RBC and other development programs, and updates to annual product revenue guidance.
Cerus’ periodic reports on Form 10-K and Form 10-Q, referenced in company press releases, include sections such as “Risk Factors” that discuss uncertainties related to commercialization of the INTERCEPT Blood System, regulatory approvals for the INTERCEPT RBC system, development of technologies like INT200 and lyophilized IFC, supply chain considerations, and macroeconomic and geopolitical risks.
Through this page, users can also monitor disclosures about board and leadership changes, such as those reported in Form 8-K filings covering director retirements and appointments of new board leadership roles. These documents provide context on the company’s governance structure.
Stock Titan enhances these filings with AI-powered tools that summarize lengthy documents, highlight key items such as revenue trends, development program updates, and risk factor changes, and help readers navigate complex regulatory language. Users can quickly locate information on topics like product revenue composition, government contract funding, and the status of clinical and regulatory programs related to Cerus’ INTERCEPT technologies.
Green Kevin Dennis reported acquisition or exercise transactions in this Form 4 filing.
CERUS CORP Chief Financial Officer Kevin Dennis Green received an equity grant of 200,000 shares of common stock. The award was made at a stated price of $0.00 per share as a stock-based compensation grant, not a market purchase or sale.
The grant was issued in the form of restricted stock units, each representing a contingent right to one share of Cerus common stock. These RSUs vest in full one year from the grant date, provided he continues serving the company through that vesting date. Following this grant, he directly holds 1,240,551 common shares.
Jensen Chrystal reported acquisition or exercise transactions in this Form 4 filing.
CERUS CORP Chief Legal Officer Chrystal Jensen received a stock-based compensation award. On April 1, 2026, Jensen was granted 200,000 shares of Common Stock in the form of restricted stock units at a stated price of $0.00 per share.
The RSUs represent a right to receive one share of common stock for each unit and vest in full one year from the grant date, as long as Jensen remains in continuous service. After this grant, Jensen directly holds 1,146,131 shares of CERUS CORP common stock.
Cerus Corp Schedule 13G/A amendment: The Vanguard Group reports zero beneficial ownership of Cerus Corp common stock following an internal realignment. The filing states that, after the January 12, 2026 realignment, certain Vanguard subsidiaries will report holdings separately and Vanguard no longer is deemed to beneficially own shares held by those subsidiaries.
The filing is signed by Vanguard's Head of Global Fund Administration on March 26, 2026, and lists 0 shares and 0% ownership with no voting or dispositive power.
Soleus Capital Master Fund, L.P. and affiliated filers report beneficial ownership of 9,828,700 shares of Cerus Corporation common stock, representing 5.1% of the class based on 192,171,776 shares outstanding as of February 5, 2026.
The filing indicates shared voting and shared dispositive power over 9,828,700 shares among Soleus entities and Guy Levy. The filers state the shares are held directly by the Master Fund and include a standard disclaimer that affiliated entities and Mr. Levy disclaim beneficial ownership except for purposes of Section 13(d).
Cerus Corp Chief Legal Officer Chrystal Jensen reported an open-market sale of 113,008 shares of Common Stock on March 12, 2025. The weighted average sales price was $1.6572 per share, with individual trades ranging from $1.62 to $1.73 per share.
According to the disclosure, these shares were sold under an instruction intended to comply with Rule 10b5-1 to cover statutory tax withholding obligations and related brokerage fees tied to the vesting of restricted stock units, and are described as not a discretionary sale. Following the transactions, Jensen directly holds 946,131 shares of Cerus common stock.
Cerus Corp Chief Operating Officer Vivek K. Jayaraman reported an open‑market sale of 165,200 shares of common stock on March 12, 2026 at a weighted average price of $1.6572 per share. According to the filing, the sale was executed under an instruction intended to comply with Rule 10b5‑1 and was made to cover statutory tax withholding obligations and related brokerage fees arising from the vesting of restricted stock units, rather than as a discretionary sale. After this transaction, he directly holds 1,747,674 shares of Cerus common stock.
CERUS CORP President and CEO William Mariner Greenman reported an open-market sale of 447,757 shares of common stock on March 12, 2026 at a weighted average price of $1.6572 per share. The footnotes state the instruction was intended to comply with Rule 10b5-1 and was elected on the grant date to cover statutory tax withholding obligations and brokerage fees tied to the vesting of restricted stock units, so it was not a discretionary sale. After this transaction, he directly owned 4,998,493 shares of Cerus common stock.
Cerus Corporation’s Chief Financial Officer Kevin Dennis Green reported an open-market sale of 127,544 shares of Common Stock at a weighted average price of $1.6572 per share. According to the disclosure, these shares were sold under an instruction intended to comply with Rule 10b5-1.
The filing explains the sale was elected on the date of grant to cover statutory tax withholding obligations and related brokerage fees tied to the vesting of certain restricted stock units, and is not a discretionary sale by the CFO. After this transaction, he directly holds 1,040,551 shares of Cerus common stock.
CERUS CORP Chief Medical Officer Benjamin Richard J reported an open-market sale of 101,740 shares of Common Stock at a weighted average price of $1.6572 per share. After this transaction, he directly holds 777,361 shares.
According to the footnotes, these shares were sold under an instruction intended to comply with Rule 10b5-1 that was elected on the grant date to cover statutory tax withholding obligations and related brokerage fees tied to the vesting of restricted stock units, and are described as not a discretionary sale. The sales occurred in multiple trades at prices ranging from $1.62 to $1.73 per share.
Cerus Corporation has appointed Vivek Jayaraman, currently Chief Operating Officer, as its next President and Chief Executive Officer effective July 1, 2026. On that date, current CEO and Board Chair William “Obi” Greenman will transition to the role of Executive Chairman, and Jayaraman will join the Board.
Under a new letter agreement effective March 11, 2026, Jayaraman will receive an annual base salary of $740,000, a target annual bonus opportunity of up to 80% of base salary starting in 2027, and will be eligible for equity incentives. These include a promotion equity award with a target value of $2,000,000 (75% time-based and 25% performance-based restricted stock units) and a one-time promotional performance-based award with a target value of $1,000,000. The number of shares for these awards will be based on the 30-day average closing price of Cerus common stock, but not less than $2.50 per share for calculation purposes.
If Jayaraman is terminated without cause or resigns for good reason, he may receive 12 months of base salary, a prorated annual bonus in certain cases, up to 12 months of COBRA premium support or equivalent cash payments, and full vesting of unvested time-based and performance-based restricted stock units, including in connection with a qualifying change in control.